Statins and the Kidney: Friend or Foe?

Blood Purification

Volumn 43, Issue 1-3, 2017, Pages 91-96

  Honore, Patrick M ^a   Jacobs, Rita ^a   Hendrickx, Inne ^a   De Waele, Elisabeth ^a   Van Gorp, Viola ^a   De Regt, Jouke ^a   Spapen, Herbert D ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Acute kidney injury; Cardiorenal syndrome; Chronic kidney disease; Contrast induced nephropathy; End stage renal disease; Rhabdomyolysis; Statins

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ANTIOXIDANT; ATORVASTATIN; CHOLESTEROL; GENTAMICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ACUTE KIDNEY FAILURE; CARDIORENAL SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY FAILURE; CONTRAST INDUCED NEPHROPATHY; CORONARY ANGIOGRAPHY; END STAGE RENAL DISEASE; HEART SURGERY; HEMODIALYSIS; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FUNCTION; META ANALYSIS (TOPIC); MORTALITY; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SECONDARY PREVENTION; CARDIOVASCULAR DISEASES; DRUG EFFECTS; KIDNEY; KIDNEY DISEASES;

CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; KIDNEY DISEASES;

EID: 85006321406     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000453577     Document Type: Review

References (43)

1. Vaughan CJ, Gotto AM Jr: Update on statins: 2003. Circulation 2004;110:886-892.
2. Bedi O, Dhawan V, Sharma PL, Kumar P: Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn Schmiedebergs Arch Pharmacol 2016;389:695-712.
3. Teshima CA, Watanabe M, Nakamura SH, Vattimo Mde F: Renoprotective effect of statin: a ischemia-reperfusion animal model. Rev Bras Ter Intensiva 2010;22:245-249.
4. Honore PM, Jacobs R, Hendrickx I, De Waele E, Van Gorp V, Spapen HD: Peri-operative fluid strategy and post-operative acute kidney injury in cardiac surgery patients: any role for pre-operative statin therapy? Crit Care 2015;19:453.
5. Huffmyer JL, Mauermann WJ, Thiele RH, Ma JZ, Nemergut EC: Preoperative statin administration is associated with lower mortality and decreased need for postoperative hemodialysis in patients undergoing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2009;23:468-473.
6. Garwood S: Statins and cardiac surgery. J Cardiothorac Vasc Anesth 2010;24:909-912.
7. Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 2013;346:f880.
8. Virani SS, Nambi V, Polsani VR, Lee VV, Elayda M, Kohsaka S, et al. Preoperative statin therapy decreases risk of postoperative renal insufficiency. Cardiovasc Ther 2010;28:80-86.
9. Argalious M, Xu M, Sun Z, Smedira N, Koch CG: Preoperative statin therapy is not associated with a reduced incidence of postoperative acute kidney injury after cardiac surgery. Anesth Analg 2010;111:324-330.
10. Nemati MH, Astaneh B: The effects of preoperative statins on the incidence of postoperative acute kidney injury in patients undergoing cardiac surgeries. Interact Cardiovasc Thorac Surg 2015;21:493-498.
11. Mithani S, Kuskowski M, Slinin Y, Ishani A, McFalls E, Adabag S: Dose-dependent effect of statins on the incidence of acute kidney injury after cardiac surgery. Ann Thorac Surg 2011;91:520-525.
12. Wang J, Gu C, Gao M, Yu W, Yu Y: Preoperative statin therapy and renal outcomes after cardiac surgery: a meta-analysis and meta-regression of 59, 771 patients. Can J Cardiol 2015;31:1051-1060.
13. Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, Du J, Guarguagli S, Hill M, Chen Z, Collins R, Casadei B: Perioperative rosuvastatin in cardiac surgery. N Engl J Med 2016;374:1744-1753.
14. Billings FT 4th, Hendricks PA, Schildcrout JS, Shi Y, Petracek MR, Byrne JG, Brown NJ: High-dose perioperative atorvastatin and acute kidney injury following cardiac surgery: a randomized clinical trial. JAMA 2016;315:877-888.
15. Park JH, Shim JK, Song JW, Soh S, Kwak YL: Effect of atorvastatin on the incidence of acute kidney injury following valvular heart surgery: a randomized, placebo-controlled trial. Intensive Care Med 2016;42:1398-1407.
16. Argalious MY, Dalton JE, Sreenivasalu T, O'Hara J, Sessler DI: The association of preoperative statin use and acute kidney injury after noncardiac surgery. Anesth Analg 2013;117:916-923.
17. Pan SY, Wu VC, Huang TM, Chou HC, Ko WJ, Wu KD, et al. NSARF Group: Effect of preoperative statin therapy on postoperative acute kidney injury in patients undergoing major surgery: systemic review and meta-analysis. Nephrology (Carlton) 2014;19:750-763.
18. Chyou AC, Thodge A, Feldman DN, Swaminathan RV: Statins in the prevention of contrast-induced nephropathy. Curr Treat Options Cardiovasc Med 2015;17:375.
19. Fu M, Dai W, Ye Y, Lu Q, He W: High dose of atorvastatin for the treatment of contrast-induced nephropathy after carotid artery stenting. Am J Ther 2015, Epub ahead of print.
20. Marenzi G, Cosentino N, Werba JP, Tedesco CC, Veglia F, Bartorelli AL: A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes. Int J Cardiol 2015;183:47-53.
21. Athyros VG, Katsiki N, Tziomalos K, Karagiannis A: Preventing cardio-renal syndrome rather than treating it: could statins play a role? Open Cardiovasc Med J 2011;5:226-230.
22. Yagi S, Aihara K, Ikeda Y, Akaike M, Sata M, Matsumoto T: Effects of statins on cardiorenal syndrome. Int J Vasc Med 2012;2012:162545.
23. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Sao Paulo Med J 2015;133:541-542.
24. Castilla-Guerra L, Del Carmen Fernandez-Moreno M, Colmenero-Camacho MA: Statins in stroke prevention: present and future. Curr Pharm Des 2016;22:4638-4644.
25. Law M, Rudnicka AR: Statin safety: a systematic review. Am J Cardiol 2006;97:52C-60C.
26. Ozbek E, Cekmen M, Ilbey YO, Simsek A, Polat EC, Somay A: Atorvastatin prevents gentamicin-induced renal damage in rats through the inhibition of p38-MAPK and NF-kappaB pathways. Ren Fail 2009;31:382-392.
27. Jabbari M, Rostami Z, Jenabi A, Bahrami A, Mooraki A: Simvastatin ameliorates gentamicin-induced renal injury in rats. Saudi J Kidney Dis Transpl 2011;22:1181-1186.
28. Acharya T, Huang J, Tringali S, Frei CR, Mortensen EM, Mansi IA: Statin use and the risk of kidney disease with long-term follow-up (8.4-year study). Am J Cardiol 2016;117:647-655.
29. Su X, Zhang L, Lv J, Wang J, Hou W, Xie X, et al. Effect of statins on kidney disease outcomes: a systematic review and meta-analysis. Am J Kidney Dis 2016;67:881-892.
30. Chung YH, Lee YC, Chang CH, Lin MS, Lin JW, Lai MS: Statins of high versus low cholesterol-lowering efficacy and the development of severe renal failure. Pharmacoepidemiol Drug Saf 2013;22:583-592.
31. Thompson PD, Clarkson P, Karas RH: Statin-associated myopathy. JAMA 2003;289:1681-1690.
32. Kato K, Onodera K, Iwasaki Y, Matsuda M, Kawakami T, Higuchi M, et al. Pravastatin-induced rhabdomyolysis and purpura fulminans in a patient with chronic renal failure. Int J Surg Case Rep 2015;8C:84-87.
33. Annigeri RA, Mani RM: Acute interstitial nephritis due to statin and its class effect. Indian J Nephrol 2015;25:54-56.
34. van Zyl-Smit R, Firth JC, Duffield M, Marais AD: Renal tubular toxicity of HMG-CoA reductase inhibitors. Nephrol Dial Transplant 2004;19:3176-3179.
35. National Kidney Foundation: KDOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. www.kidney.org/professionals/Kdoqi/guidelines-lipids/index.htm (accessed May 2016).
36. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-2192.
37. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, et al. German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248.
38. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-1407.
39. Lin SY, Lin CL, Hsu WH, Lin CC, Chang CT, Kao CH: Association of statin use and the risk of end-stage renal disease: a nationwide Asian population-based case-control study. Eur J Intern Med 2016;31:68-72.
40. Vaziri ND, Norris KC: Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations. Blood Purif 2013;35:31-36.
41. Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass A, et al. SHARP Collaborative Group: Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol 2014;25:1825-1833.
42. National Kidney Foundation: KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 2012;60:850-886.
43. Kim JJ, Langworthy DR, Hennessey EK: Clinical implications of statin therapy in patients undergoing hemodialysis. Am J Health Syst Pharm 2014;71:703-710.